학술논문
Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo.
Document Type
Article
Author
Zola Matuvanga, Trésor; Mariën, Joachim; Larivière, Ynke; Osang'ir, Bernard Isekah; Milolo, Solange; Meta, Rachel; Esanga, Emmanuel; Maketa, Vivi; Matangila, Junior; Mitashi, Patrick; Ahuka Mundeke, Steve; Muhindo-Mavoko, Hypolite; Muyembe Tamfum, Jean-Jacques; Van Damme, Pierre; Van Geertruyden, Jean-Pierre
Source
Subject
*MEDICAL personnel
*EBOLA virus
*SEROPREVALENCE
*VACCINE trials
*EBOLA virus disease
*VIRAL antibodies
*
*
*
*
*
Language
ISSN
1932-6203
Abstract
Introduction: A serosurvey among health care providers (HCPs) and frontliners of an area previously affected by Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC) was conducted to assess the seroreactivity to Ebola virus antigens. Methods: Serum samples were collected in a cohort of HCPs and frontliners (n = 698) participants in the EBL2007 vaccine trial (December 2019 to October 2022). Specimens seroreactive for EBOV were confirmed using either the Filovirus Animal Nonclinical Group (FANG) ELISA or a Luminex multiplex assay. Results: The seroreactivity to at least two EBOV-Mayinga (m) antigens was found in 10 (1.4%: 95% CI, 0.7–2.6) samples for GP-EBOV-m + VP40-EBOV-m, and 2 (0.3%: 95% CI, 0.0–1.0) samples for VP40-EBOV-m + NP-EBOV-m using the Luminex assay. Seroreactivity to GP-EBOV-Kikwit (k) was observed in 59 (8.5%: 95%CI, 6.5–10.9) samples using FANG ELISA. Conclusion: In contrast to previous serosurveys, a low seroprevalence was found in the HCP and frontline population participating in the EBL2007 Ebola vaccine trial in Boende, DRC. This underscores the high need for standardized antibody assays and cutoffs in EBOV serosurveys to avoid the broad range of reported EBOV seroprevalence rates in EBOV endemic areas. [ABSTRACT FROM AUTHOR]